Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CASP3 | P42574 | 2/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31418070 | 1.00 | KDM4E (1.00) | KDM4EPOLBHCAR2HTTROCK2 | |
| Pyridine SCHEMBL27492556 | 0.90 | KDM4E (0.81) | KDM4EPOLBHCAR2HTTROCK2 | |
| Trifluoroacetic Acid SCHEMBL29562620 | 0.89 | KDM4E (0.79) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL28983957 | 0.86 | KDM4E (0.74) | KDM4EPOLBHTTALDH1A1GAA | |
| SCHEMBL3824227 | 0.81 | KDM4E (0.69) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL1502567 | 0.81 | KDM4E (0.68) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL31555016 | 0.81 | KDM4E (0.68) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL6496093 | 0.81 | KDM4E (0.68) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL1095815 | 0.81 | KDM4E (0.68) | KDM4EPOLBHCAR2HTTROCK2 | |
| SCHEMBL19688299 | 0.80 | POLB (0.72) | KDM4EPOLBHCAR2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| WO-2025015420-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-01-23 | — | — | WO | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| CN-115586273-A | Compound non-target identification method based on bromine isotope labeling | 遵义医科大学 | 2023-01-10 | — | — | CN | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1183252-B1 | PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| US-6492406-B1 | PROTEIN KINASE C INHIBITORS; ANTIINFLAMMATORY AND IMMUNO-SUPPRESSIVE AGENTS | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| EP-1183252-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-03-06 | — | — | EP | disclosed |
| EP-0885222-B1 | HETEROCYCLYL-ERGOLINE DERIVATIVES AS 5-HT1A RECEPTOR LIGANDS | PHARMACIA & UPJOHN SPA (IT) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000071537-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
| US-6087371-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS ASSOCIATED WITH SEROTONINERGIC DISFUNCTIONS, SUCH AS IMPAIRMENT OF THERMOREGULATION, MEMORY FUNCTION, SLEEP DISORDERS, SATIETY CONTROL (I.E. FOOD AND BEVERAGE CONSUMPTION) | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-07-11 | — | — | US | disclosed |
| CN-1211253-A | Heterocyclyl-ergoline derivatives as 5-HT1A receptor ligands | PHARMACIA & UPJOHN SPA (IT) | 1999-03-17 | — | — | CN | disclosed |
| EP-0885222-A1 | HETEROCYCLYL-ERGOLINE DERIVATIVES AS 5-HT1A RECEPTOR LIGANDS | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030050-A1 | HETEROCYCLYL-ERGOLINE DERIVATIVES AS 5-HT1A RECEPTOR LIGANDS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885POLB 4491/4885HCAR2 1924/4885 |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | FAAH, FAAH2, MGLL | KDM4E 1807/4885POLB 4023/4885HCAR2 64/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | KDM4E 1807/4885POLB 4023/4885HCAR2 64/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | KDM4E 298/4885POLB 533/4885HCAR2 2750/4885 |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885POLB 4491/4885HCAR2 1924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.